There are shortages of an RSV vaccine for infants due to supply issues.
The Centers for Disease Control and Prevention (CDC) released a notice last week citing “limited availability” of the long-acting monoclonal antibody immunization Beyfortus (nirsevimab).
The product is recommended by the CDC for preventing disease from respiratory syncytial virus (RSV)Ā in children up to 24 monthsĀ of age.